1. Signaling Pathways
  2. Metabolic Enzyme/Protease
    Neuronal Signaling
  3. FAAH

FAAH

Fatty acid amide hydrolase

FAAH (Fatty acid amide hydrolase) is a membrane-bound protein belonging to serine hydrolase family of enzymes.FAAH is responsible for the hydrolysis of a number of important endogenous fatty acid amides, including the endogenous cannabimimetic agent anandamide (AEA), the sleep-inducing compound oleamide, and the putative anti-inflammatory agent palmitoylethanolamide (PEA). FAAH plays a significant role in termination of signalling of a class of bioactive lipids called fatty acid amides (FAAs) both in the central nervous system (CNS) and peripheral tissues.

FAAH belongs to the amidase signature (AS) superfamily and is widely distributed in multicellular eukaryotes. FAAH has a key role in the control of the cannabinoid signaling, through the hydrolysis of the endocannabinoids anandamide and in some tissues 2-arachidonoylglycerol.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-18080
    SA 47
    Inhibitor 99.0%
    SA 47 is a selective and potent inhibitor of fatty acid amide hydrolase (FAAH) and carbamate.
    SA 47
  • HY-N3033
    N-​Benzyllinolenamide
    Inhibitor 99.70%
    N-​Benzyllinolenamide is a natural macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 41.8 μM.
    N-​Benzyllinolenamide
  • HY-18013
    JNJ-40355003
    Inhibitor 99.81%
    JNJ-40355003 is a potent and selective atty acid amide hydrolase (FAAH) inhibitor.
    JNJ-40355003
  • HY-111199
    JP83
    Inhibitor 99.0%
    JP83 is an irreversible fatty acyl amide hydrolase (FAAH) inhibitor with an IC50 of 1.6 nM in competitive activity-based protein profiling (ABPP) experiments.
    JP83
  • HY-123863
    SSR411298
    Inhibitor 99.75%
    SSR411298 is an orally active, selective and reversible fatty acid amide hydrolase (FAAH) inhibitor. SSR411298 has the potential for post-traumatic stress disorder research.
    SSR411298
  • HY-121558
    JP104
    Inhibitor 99.67%
    JP104, a aryl carbamate, is an irreversible FAAH inhibitor with a pIC50 of ~8.
    JP104
  • HY-B1227R
    Carprofen (Standard)
    Inhibitor
    Carprofen (Standard) is the analytical standard of Carprofen. This product is intended for research and analytical applications. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.
    Carprofen (Standard)
  • HY-127023
    Eicosapentaenoyl serotonin
    Inhibitor 99.0%
    Eicosapentaenoyl serotonin (EPA-5-HT) is an endogenous fatty acid-serotonin conjugate lipid mediator. Eicosapentaenoyl serotonin acts as an inhibitor of fatty acid amide hydrolase (FAAH). Eicosapentaenoyl serotonin suppresses IL-17 release in Concanavalin A (HY-P2149)-stimulated human peripheral blood mononuclear cells. Eicosapentaenoyl serotonin is regulated by polyunsaturated fatty acids and modulates intestinal immunity and Th17 signaling. Eicosapentaenoyl serotonin can be used for the study of inflammatory bowel disease-related mechanisms.
    Eicosapentaenoyl serotonin
  • HY-124744
    ASP 8477
    Inhibitor 98.35%
    ASP 8477 is an orally active and selective fatty acid amide hydrolase (FAAH) inhibitor with IC50 values ​​of 3.99, 1.65, and 57.3 nM for human FAAH-1, FAAH-1 (P129T), and FAAH-2, respectively. ASP 8477 has central nervous system activity and can be used in analgesia research.
    ASP 8477
  • HY-10867
    PF-622
    Inhibitor
    PF-622 is a selective FAAH inhibitor, and can be used for study of analgesic and anxiolytic/antidepressant.
    PF-622
  • HY-146342
    FAAH/MAGL-IN-3
    Inhibitor
    FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC50 values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability.
    FAAH/MAGL-IN-3
  • HY-148909
    Isopropyl dodec-11-enylfluorophosphonate
    Inhibitor
    Isopropyl dodec-11-enylfluorophosphonate (IDEFP) is an organophosphorus ester that antagonizes the central cannabinoid receptor (CB1) and inhibits FAAH with similar potencies (IC50 = 2 nM).
    Isopropyl dodec-11-enylfluorophosphonate
  • HY-157766
    FAAH/TRPV1 blocker-1
    Inhibitor
    FAAH/TRPV1 blocker-1 (compound 2R) is a dual FAAH/TRPV1 blocker, with IC50 of 0.12 and 94.9 μM, respectively. FAAH/TRPV1 blocker-1 plays an important role in analgesic and anti-inflammatory research.
    FAAH/TRPV1 blocker-1
  • HY-175816
    5-HT6R/FAAH modulator 1
    Inhibitor
    5-HT6R/FAAH modulator 1 is a selective serotonin 5-HT6 receptor ligand and the fatty acid amide hydrolase (FAAH) enzyme inhibitor. 5-HT6R/FAAH modulator 1 shows a pKi of 6.33 (5-HT6) and a pIC50 valuesof 6.29 (FAAH). 5-HT6R/FAAH modulator 1 also slightly inhibits acetylcholinesterase (AChE) or butyrylcholinesterase (BChE) enzymes (pIC50 = 5.12). 5-HT6R/FAAH modulator 1 can inhibit apoptosis and reduce ROS levels. 5-HT6R/FAAH modulator 1 can be used for the research of neurological disease, such as Alzheimer’s disease (AD).
    5-HT6R/FAAH modulator 1
  • HY-116710
    3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone
    Inhibitor
    3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone (compound 45) is a potential inhibitor of fatty acid amide hydrolase (FAAH) (pI50: 5.89) and is active against CB(1) and CB(2) ) Lack of affinity for cannabinoid receptors.
    3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone
  • HY-B1227S1
    Carprofen-13C,d3
    Carprofen-13C,d3 is the deuterium and 13C labeled Carprofen. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.
    Carprofen-<sup>13</sup>C,d<sub>3</sub>
  • HY-144738
    Dual FAAH/sEH-IN-1
    Inhibitor
    Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC50 values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase.
    Dual FAAH/sEH-IN-1
  • HY-149654
    FAAH/cPLA2α-IN-1
    Inhibitor
    FAAH/cPLA2α-IN-1 is a dual inhibitor of FAAH and cPLA2α with IC50s of 32 and 47 nM, respectively.
    FAAH/cPLA2α-IN-1
  • HY-102054
    Acetylhydrolase-IN-1
    Inhibitor
    Acetylhydrolase-IN-1 is a 1-Alkyl-2-acetylglycerophosphocholine esterase (Alkylacetyl-GPC: acetylhydrolase) inhibtor.
    Acetylhydrolase-IN-1
  • HY-115004
    MM-433593
    MM-433593 is a potent and selective inhibitor of fatty acid amide hydrolase-1 (FAAH-1) that is orally administered to inhibit pain, inflammation, and related disorders. Pharmacokinetic studies of MM-433593 in macaques revealed a biphasic elimination profile with a rapid distribution phase and a slower elimination phase, with a systemic clearance of 8-11 mL/min/kg. MM-433593 exhibits moderate oral bioavailability (14-21%) and its metabolism primarily involves oxidation of the methyl group on the indole ring, resulting in a variety of sulfate, glucuronide, or glutathione-conjugated metabolites.
    MM-433593
Cat. No. Product Name / Synonyms Application Reactivity